Mutational processes that alter large genomic regions occur frequently in developing
tumors. They range from simple copy number gains and losses to the shattering and …

BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and
durable responses in multiple myeloma. However, relapse following therapy is frequently …

Karyotype complexity has major prognostic value in many malignancies. There is no
consensus on the definition of a complex karyotype, and the prognostic impact of karyotype …

Abstract Background BCMA CAR-T is highly effective for relapsed/refractory multiple
myeloma (R/R-MM) and significantly improves the survival of patients. However, the short …

Multiple myeloma (MM) is still incurable partially due to lacking effective therapeutic targets.
Aberrant N6-methyladenosine (m6A) RNA modification plays a vital role in many cancers …

Several kinds of stress promote the formation of three‐stranded RNA: DNA hybrids called R‐
loops. Insufficient clearance of these structures promotes genomic instability and DNA …

Extramedullary multiple myeloma (or extramedullary disease, EMD) is an aggressive form of
multiple myeloma (MM) that occurs when malignant plasma cells become independent of …

Multiple myeloma (MM) is the second‐ranking malignancy in hematological tumors. The
pathogenesis of MM is complex with high heterogeneity, and the development of the …

Multiple myeloma (MM) progression and drug resistance depend on the crosstalk between
MM cells and bone marrow (BM) fibroblasts (FBs). During monoclonal gammopathy of …

Epstein-Barr virus (EBV) is a widespread human herpes virus associated with lymphomas
and epithelial cell cancers. It establishes two separate infection phases, latent and lytic, in …